Priya Sharma Vakharia

May 31, 2024 | retinalphysician.com | Priya Sharma Vakharia |David Eichenbaum

Intravitreal injection therapy of anti‒vascular endothelial growth factor (anti-VEGF) continues to be one of the most effective and common procedures performed by vitreoretinal specialists.

Apr 25, 2024 | retinalphysician.com | Priya Sharma Vakharia

This article was originally published in a sponsored newsletter. Anti-complement injections represent an interesting new territory in retina care. Typically, patients who receive intravitreal injections for wet AMD and diabetic macular edema notice some improvement in their vision or diagnostic photos. However, it is likely that vision in geographic atrophy (GA) patients will still worsen over time despite treatment. How do we motivate patients to initiate therapy and keep coming back to the clinic?

Mar 8, 2024 | retinalphysician.com | Priya Sharma Vakharia

This article was originally published in a sponsored newsletter. We are approaching 1 year since pegcetacoplan (Syfovre; Apellis Pharmaceuticals) and avacincaptad pegol (Izervay; Iveric Bio/Astellas) were approved for the treatment of geographic atrophy (GA) secondary to dry AMD. Now that we have increased understanding and adoption of these therapies, it is time to tackle real-world practice and workflow questions.

Jan 15, 2024 | eyetube.net | Priya Sharma Vakharia

Editorially Independent content supported with advertising by Genentech Switch Case: 66-Year-Old Man With Wet AMD Priya Sharma Vakharia, MD Show Description + Does switching from aflibercept 2 mg (Eylea, Regeneron) to faricimab (Vabysmo, Genentech/Roche) in a wet AMD patient with slight recurrent fluid allow extended treatment intervals? Priya Sharma Vakharia, MD, shares a real-world case from her clinic, which sparks a discussion about dosing strategies when switching to a new agent.